Atrasentan | Chinook Therapeutics
Atrasentan | Chinook Therapeutics
Atrasentan - an overview | ScienceDirect Topics
SONAR propels endothelin A receptor antagonists to success | Nature Reviews Nephrology
Pathophysiological role of endothelin in chronic kidney disease (CKD)... | Download Scientific Diagram
Atrasentan-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Atrasentan, an endothelin receptor antagonist selective for subtype A (ETA) used to treat cancer, pulmonary hypertension, diabetic kidney diseases and ...
Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy | American Society of Nephrology
New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction - ScienceDirect
Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition | SpringerLink
Endothelin A Receptor Antagonist, Atrasentan, Attenuates Renal and Cardiac Dysfunction in Dahl Salt-Hypertensive Rats in a Blood Pressure Independent Manner
Ligand search results | IUPHAR/BPS Guide to PHARMACOLOGY
Atrasentan treatment signi fi cantly decreases albuminuria. (A) UACR... | Download Scientific Diagram
eraedta20 - Twitter Search / Twitter
JCM | Free Full-Text | Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy | HTML
Endothelin Receptors and Their Antagonists - ScienceDirect
Endocrine aspects of bone metastases - The Lancet Diabetes & Endocrinology
JCM | Free Full-Text | Therapeutic Advances in Diabetic Nephropathy | HTML
Atrasentan treatment modulates of fi ce and 24-hour ambulatory blood... | Download Scientific Diagram
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. - Abstract - Europe PMC
Atrasentan - Wikipedia
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial - The Lancet
Atrasentan | Chinook Therapeutics
